Evicenter
P&T meetings

Tirabrutinib

Primary central nervous system lymphoma

Regulatory submission
NDA submitted December 2025
72 sources

Section 6 of 6

References

72 sources

  1. Akimoto et al. (2026) (opens in a new tab)
  2. Arakawa et al. (2023) (opens in a new tab)
  3. Arakawa et al. (2023) (opens in a new tab)
  4. Cayman Chemical safety data sheet (2025) (opens in a new tab)
  5. Čermáková et al. (2025) (opens in a new tab)
  6. Chen et al. (2022) (opens in a new tab)
  7. Deciphera Pharmaceuticals (opens in a new tab)
  8. Deciphera Pharmaceuticals (2026) (opens in a new tab)
  9. Dhillon (2020) (opens in a new tab)
  10. Doolittle et al. (2013) (opens in a new tab)
  11. FDA Orphan Drug Designations and Approvals (2023) (opens in a new tab)
  12. Ferreri et al. (2024) (opens in a new tab)
  13. Gilead Sciences protocol GS-US-401-2076 (2019) (opens in a new tab)
  14. Guo et al. (2024) (opens in a new tab)
  15. Hoang-Xuan et al. (2023) (opens in a new tab)
  16. Hsiao et al. (2026a) (opens in a new tab)
  17. Hsiao et al. (2026b) (opens in a new tab)
  18. Iizuka-Honma et al. (2023) (opens in a new tab)
  19. Ikegawa et al. (2025) (opens in a new tab)
  20. Ishi et al. (2025) (opens in a new tab)
  21. Kawabata et al. (2026) (opens in a new tab)
  22. Kawabata et al. (2026) (opens in a new tab)
  23. Kawasaki et al. (2025) (opens in a new tab)
  24. Kawauchi et al. (2025) (opens in a new tab)
  25. KEGG (opens in a new tab)
  26. Khairunnisa et al. (2024) (opens in a new tab)
  27. Kitamura and Kuyama (2022) (opens in a new tab)
  28. Kozaki et al. (2023) (opens in a new tab)
  29. Liao et al. (2024) (opens in a new tab)
  30. Liclican et al. (2020) (opens in a new tab)
  31. Lv et al. (2022) (opens in a new tab)
  32. Matsunuma et al. (2026) (opens in a new tab)
  33. Meng et al. (2022) (opens in a new tab)
  34. Motomura et al. (2024) (opens in a new tab)
  35. Nagane et al. (2024) (opens in a new tab)
  36. Nakagawa et al. (2022) (opens in a new tab)
  37. Nakagawa et al. (2022) (opens in a new tab)
  38. Narita et al. (2021) (opens in a new tab)
  39. National Cancer Institute Drug Dictionary (opens in a new tab)
  40. National Cancer Institute NCI-2021-14196 (opens in a new tab)
  41. National Cancer Institute PDQ health professional version (opens in a new tab)
  42. National Cancer Institute PDQ patient version (opens in a new tab)
  43. Nayak et al. (2025a) (opens in a new tab)
  44. Nayak et al. (2025b) (opens in a new tab)
  45. Nayak et al. (2026) (opens in a new tab)
  46. Okawara et al. (2025) (opens in a new tab)
  47. Okita et al. (2021) (opens in a new tab)
  48. Ono et al. (2026) (opens in a new tab)
  49. Ono et al. (2026) (opens in a new tab)
  50. ONO Pharma and Deciphera Pharmaceuticals (2025) (opens in a new tab)
  51. ONO Pharma USA (2023) (opens in a new tab)
  52. ONO Pharma USA (2025) (opens in a new tab)
  53. Ono Pharmaceutical (opens in a new tab)
  54. Ono Pharmaceutical (opens in a new tab)
  55. Ono Pharmaceutical (2026) (opens in a new tab)
  56. PMDA review report (2020) (opens in a new tab)
  57. PMDA revision of precautions (2024) (opens in a new tab)
  58. PROSPECT study website (opens in a new tab)
  59. Taiwan Food and Drug Administration assessment report (opens in a new tab)
  60. Tan et al. (2025) (opens in a new tab)
  61. University of California, Irvine (opens in a new tab)
  62. Wang et al. (2025) (opens in a new tab)
  63. Yamasaki et al. (2025a) (opens in a new tab)
  64. Yamasaki et al. (2025a) (opens in a new tab)
  65. Yamasaki et al. (2025b) (opens in a new tab)
  66. Yashima et al. (2026) (opens in a new tab)
  67. Yasu et al. (2026) (opens in a new tab)
  68. Yonezawa et al. (2024) (opens in a new tab)
  69. Yonezawa et al. (2024) (opens in a new tab)
  70. Yoshioka et al. (2021) (opens in a new tab)
  71. Yoshioka et al. (2022) (opens in a new tab)
  72. Zhang et al. (2024) (opens in a new tab)